METHODS FOR TREATING DRAVET SYNDROME
Provided herein are methods of treating Dravet syndrome that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.
1 . A method of treating Dravet syndrome in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a T-type calcium channel antagonist.
2 - 3 . (canceled)
4 . The method of claim 1 , wherein the T-type calcium channel antagonist is a small molecule, an antibody, or a siRNA.
5 - 9 . (canceled)
10 . The method of claim 1 , wherein the T-type calcium channel antagonists antagonize a T-type calcium channel in a cell when the membrane potential of the cell is in the range from about −60 mV to about −30 mV or from about −100 mV to about −80 mV.
11 . The method of claim 1 , wherein the T-type calcium channel antagonist is one or more antagonists selected from the group consisting of mibefradil, MK-8998, diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, gallopamil, verapamil, tiapamil, pimozide, thioridazine, NNC 55-0396, TTL-1177, anandamide, pimozide, penfluridol, clopimozide, fluspirilene, haloperidol, droperidol, benperidol, triperidol, melperone, lenperone, azaperone, domperidone, antrafenine, aripiprazole, ciprofloxacin, dapiprazole, dropropizine, etoperidone, itraconazole, ketoconazole, levodropropizine, mepiprazole, naftopidil, nefazodone, niaprazine, oxypertine, posaconazole, trazodone, urpidil, vesnarinone, manidipine, nilvadipine, benidipine, efonidipine, flunarizine, anandamide, lomerizine, zonisamide, U-92032, tetralol, mibefradil, NNC 55-0396, TTA-A2, TTA-A8, TTA-P1, 4-aminomethyl-4-fluoropiperidine (TTA-P2), TTA-Q3, TTA-Q6, MK-5395, MK-6526, MK-8998, Z941, Z944, phensuximide, mesuximide, desmethylmethsuximide, efonidipine, trimethadione, dimethadione, ABT-639, TTL-1177, KYSO5044, nickel, and kurtoxin, and combinations thereof.
12 . The method of claim 1 , wherein the T-type calcium channel antagonist is mibefradil or MK-8998 TTA-A2.
13 . The method of claim 1 , wherein the treatment comprises reducing or ameliorating at least one neurological symptom in the subject.
14 . The method of claim 13 , wherein the neurological symptom comprises one or more of seizure, hyperactivity, impulsiveness, autistic behavior, somnolence, insomnia, psychomotor delay, ataxia cognitive impairment, neurological development, developmental delay, and impaired behavior.
15 - 16 . (canceled)
17 . The method of claim 14 , wherein the neurological symptom comprises a seizure, and wherein the seizure is a febrile seizure.
18 - 36 . (canceled)
37 . The method of claim 1 , wherein the treatment comprises improving the memory of the subject.
38 . The method of claim 37 , wherein the treatment comprises improving the short-term memory or the working memory of the subject.
39 - 46 .
47 . The method of claim 1 , further comprising administering to the subject an additional therapeutic agent.
48 . The method of claim 47 , wherein the additional therapeutic agent is an additional T-type calcium channel inhibitor.
49 . The method of claim 48 , wherein the additional therapeutic agent is an anticonvulsive agent.
50 . The method of claim 49 , wherein the anticonvulsive agent is selected from acetazolamide, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, lacosamide, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, pregabalin, primidone, retigabine, rufinamide, valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.
51 . The method of claim 1 , further comprising administering an additional therapy selected from the group consisting of a ketogenic diet, physical therapy, occupational therapy, communication therapy, and behavioral therapy.